DK2449098T3 - Oprensning og isolering af rekombinante oxalat-nedbrydende enzymer og sprøjtetørrede partikler indeholdende oxalat-nedbrydende enzymer - Google Patents
Oprensning og isolering af rekombinante oxalat-nedbrydende enzymer og sprøjtetørrede partikler indeholdende oxalat-nedbrydende enzymer Download PDFInfo
- Publication number
- DK2449098T3 DK2449098T3 DK10744865.6T DK10744865T DK2449098T3 DK 2449098 T3 DK2449098 T3 DK 2449098T3 DK 10744865 T DK10744865 T DK 10744865T DK 2449098 T3 DK2449098 T3 DK 2449098T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxalate
- seq
- oxdc
- particles
- enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (10)
1. Sprøjtetørrede partikler omfattende et eller flere rekombinante proteiner valgt fra gruppen bestående af C383S- og C383A-mutanten af det rekombinante oxalat-decarboxylase-(OxDC)-vildtype-protein i henhold til SEQ. ID NO. 1 eller SEQ. ID NO. 2, eller et protein kodet af en sekvens valgt fra SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7, SEQ. ID NO. 8, SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18, eller SEQ. ID NO. 19; og et polymermateriale, hvor proteinerne er frembragt som nano- eller mikroagglomerater.
2. Sprøjtetørrede partikler ifølge krav 1, hvor det oxalat-reducerende enzym er C383S-mutanten af det rekombinante OxDC-vildtype-protein eller et protein kodet af en sekvens valgt fra SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7 eller SEQ. ID NO. 8.
3. Sprøjtetørrede partikler ifølge krav 1, hvor det oxalat-reducerende enzym er C383A-mutanten af det rekombinante OxDC-vildtype-protein eller et protein kodet afen sekvens valgt fra SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18 eller SEQ. ID NO. 19.
4. Sprøjtetørrede partikler ifølge et hvilket som helst af kravene 1-3, hvor aktiviteten af det ene eller flere oxalat-reducerende enzymer når til stede i partiklerne højst falder til omkring 30% når inkuberet i en 3,2 mg/ml pepsinopløsning med en pH på omkring 3,2 i 40 minutter, hvor den initiale aktivitet sættes til 100%.
5. Sprøjtetørrede partikler ifølge et hvilket som helst af kravene 1-4, hvor polymermaterialet er et poly(meth)akrylat.
6. Sammensætning omfattende sprøjtetørrede partikler som defineret i et hvilket som helst af kravene 1-5.
7. Sammensætningen ifølge krav 6, hvor sammensætningen er en oral dosisform.
8. Sammensætningen ifølge krav 6 eller 7 i formen af en lille pose, tablet, kapsel, tyggetablet, hurtigopløsende tablet, oralt desintegrerende tablet, væsker, sirupper, eller eliksirer eller andet leveringsformat.
9. Sammensætningen ifølge et hvilket som helst af kravene 6-8 til anvendelse i en fremgangsmåde til behandling af et menneskeligt eller dyreindivid ved at reducere oxalat til stede i maven for derved at reducere absorptionen af oxalatet, hvilken fremgangsmåde omfatter oral administration af sammensætningen til maven af det menneskelige eller dyreindivid.
10. Sammensætningen til anvendelse ifølge krav 9, hvor reduktion af absorption af oxalat tilvejebringer behandling af en oxalat-relateret tilstand valgt fra gruppen bestående af hyperoxaluri, absorptiv hyperoxaluri, enterisk hyperoxaluri, primær hyperoxaluri, idiopatisk calciumoxalat-nyrestenssygdom, urolithiasis, vulvodyni, oxalose associeret med slutstadie nyresygdom, hjertekonduktansforstyrrelse, inflammatorisk tarmsygdom, Crohns sygdom, ulcerøs colitis, postoperative gastrointestinale tilstande, og postoperative bariatriske tilstande, postoperative fedme tilstande, eller postantibiotika behandling.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09164430.2A EP2270138B1 (en) | 2009-07-02 | 2009-07-02 | Purification and isolation of recombinant oxalate degrading enzymes |
US12/497,275 US8431122B2 (en) | 2009-07-02 | 2009-07-02 | Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes |
PCT/EP2010/003864 WO2011000523A1 (en) | 2009-07-02 | 2010-07-01 | Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2449098T3 true DK2449098T3 (da) | 2017-03-06 |
Family
ID=43028177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10744865.6T DK2449098T3 (da) | 2009-07-02 | 2010-07-01 | Oprensning og isolering af rekombinante oxalat-nedbrydende enzymer og sprøjtetørrede partikler indeholdende oxalat-nedbrydende enzymer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20120189604A1 (da) |
EP (1) | EP2449098B1 (da) |
JP (2) | JP2012531186A (da) |
CN (2) | CN104805067A (da) |
BR (1) | BRPI1013956B8 (da) |
CA (2) | CA2767039C (da) |
DK (1) | DK2449098T3 (da) |
ES (1) | ES2617917T3 (da) |
HK (1) | HK1210805A1 (da) |
HU (1) | HUE030905T2 (da) |
IL (1) | IL216873A (da) |
IN (1) | IN2012DN00592A (da) |
LT (1) | LT2449098T (da) |
PL (1) | PL2449098T3 (da) |
PT (1) | PT2449098T (da) |
WO (1) | WO2011000523A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8431122B2 (en) | 2009-07-02 | 2013-04-30 | Oxthera Intellectual Property Ab | Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes |
US9714456B2 (en) * | 2013-01-18 | 2017-07-25 | Allena Pharmaceuticals, Inc. | Crystallized oxalate decarboxylase and methods of use |
CN103540569A (zh) * | 2013-06-05 | 2014-01-29 | 黄虹寓 | 结石酶及其制备方法 |
US11077238B2 (en) * | 2013-06-07 | 2021-08-03 | Allena Pharmaceuticals, Inc. | Compositions, methods, and devices for dialysis |
CN107254453B (zh) * | 2014-12-22 | 2019-10-25 | 武汉康复得生物科技股份有限公司 | 一种在生理pH条件下有活力的草酸氧化酶及其应用 |
CN116124853B (zh) * | 2022-11-07 | 2024-01-16 | 东北农业大学 | 一种检测草酸的电化学生物传感器、制备方法及应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8486389B2 (en) * | 1997-05-23 | 2013-07-16 | Oxthera, Inc. | Compositions and methods for treating or preventing oxalate-related disease |
US6929940B1 (en) * | 2002-08-20 | 2005-08-16 | University Of Florida Research Foundation, Inc. | Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use |
AU2003274918A1 (en) * | 2002-08-20 | 2004-03-11 | University Of Florida | Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use |
AU2005339139A1 (en) * | 2005-12-14 | 2007-06-21 | Oxthera, Inc. | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease |
WO2007075447A2 (en) * | 2005-12-16 | 2007-07-05 | Oxthera, Inc. | Compositions and methods for oxalate reduction |
ES2412254T3 (es) * | 2006-08-02 | 2013-07-10 | Altus Pharmaceuticals Inc. | Oxalato-descarboxilasa cristalizada y métodos de uso |
-
2010
- 2010-07-01 IN IN592DEN2012 patent/IN2012DN00592A/en unknown
- 2010-07-01 CA CA2767039A patent/CA2767039C/en not_active Expired - Fee Related
- 2010-07-01 HU HUE10744865A patent/HUE030905T2/en unknown
- 2010-07-01 CA CA3012811A patent/CA3012811A1/en not_active Abandoned
- 2010-07-01 JP JP2012516581A patent/JP2012531186A/ja active Pending
- 2010-07-01 BR BRPI1013956A patent/BRPI1013956B8/pt not_active IP Right Cessation
- 2010-07-01 ES ES10744865.6T patent/ES2617917T3/es active Active
- 2010-07-01 PT PT107448656T patent/PT2449098T/pt unknown
- 2010-07-01 CN CN201510140451.XA patent/CN104805067A/zh active Pending
- 2010-07-01 EP EP10744865.6A patent/EP2449098B1/en active Active
- 2010-07-01 US US13/381,430 patent/US20120189604A1/en not_active Abandoned
- 2010-07-01 DK DK10744865.6T patent/DK2449098T3/da active
- 2010-07-01 WO PCT/EP2010/003864 patent/WO2011000523A1/en active Application Filing
- 2010-07-01 PL PL10744865T patent/PL2449098T3/pl unknown
- 2010-07-01 CN CN201080029636.9A patent/CN102597225B/zh not_active Expired - Fee Related
- 2010-07-01 LT LTEP10744865.6T patent/LT2449098T/lt unknown
-
2011
- 2011-12-08 IL IL216873A patent/IL216873A/en active IP Right Grant
-
2015
- 2015-11-19 HK HK15111425.5A patent/HK1210805A1/xx unknown
- 2015-12-17 JP JP2015246402A patent/JP6220845B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102597225B (zh) | 2015-04-29 |
CN102597225A (zh) | 2012-07-18 |
HK1210805A1 (en) | 2016-05-06 |
BRPI1013956B8 (pt) | 2021-05-25 |
BRPI1013956A2 (pt) | 2019-04-09 |
PT2449098T (pt) | 2017-03-10 |
HUE030905T2 (en) | 2017-06-28 |
EP2449098A1 (en) | 2012-05-09 |
CN104805067A (zh) | 2015-07-29 |
JP2016121138A (ja) | 2016-07-07 |
IL216873A0 (en) | 2012-02-29 |
ES2617917T3 (es) | 2017-06-20 |
PL2449098T3 (pl) | 2017-06-30 |
US20120189604A1 (en) | 2012-07-26 |
IL216873A (en) | 2017-07-31 |
LT2449098T (lt) | 2017-05-25 |
WO2011000523A1 (en) | 2011-01-06 |
IN2012DN00592A (da) | 2015-06-12 |
CA2767039A1 (en) | 2011-01-06 |
CA3012811A1 (en) | 2011-01-06 |
BRPI1013956B1 (pt) | 2021-04-06 |
CA2767039C (en) | 2018-09-04 |
EP2449098B1 (en) | 2016-12-07 |
JP2012531186A (ja) | 2012-12-10 |
JP6220845B2 (ja) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10568946B2 (en) | Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes | |
JP6220845B2 (ja) | 組換えオキサレート分解酵素の精製及び単離並びにオキサレート分解酵素を含む噴霧乾燥粒子 | |
EP1976553B1 (en) | Compositions and methods for oxalate reduction | |
WO2008105911A9 (en) | Crystallized oxalate decarboxylase and methods of use | |
JP2013512249A (ja) | シュウ酸塩に関連した症状を治療する方法及び組成物 | |
EP2270138B1 (en) | Purification and isolation of recombinant oxalate degrading enzymes | |
JP2012531186A5 (da) |